Annovis Bio Inc
ANVS2.490USD
+0.080+3.28%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
50.27MValor de mercado
PerdaP/L TTM
Mais detalhes de Annovis Bio Inc Empresa
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
Informações de Annovis Bio Inc
Código da empresaANVS
Nome da EmpresaAnnovis Bio Inc
Data de listagemJan 29, 2020
CEOMaccecchini (Maria L)
Número de funcionários8
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 29
Endereço101 Lindenwood Drive, Suite 225
CidadeMALVERN
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal19355
Telefone14848753192
Sitehttps://www.annovisbio.com/
Código da empresaANVS
Data de listagemJan 29, 2020
CEOMaccecchini (Maria L)
Executivos da empresa Annovis Bio Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Independent Chairman of the Board
Independent Chairman of the Board
2.80M
+45000.00%
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Reid S. Mccarthy
Mr. Reid S. Mccarthy
Independent Director
Independent Director
--
--
Dr. Claudine E. Bruck, Ph.D.
Dr. Claudine E. Bruck, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mark White
Mr. Mark White
Director, Chief Business Officer
Director, Chief Business Officer
--
--
Dr. Cheng Fang, Ph.D.
Dr. Cheng Fang, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Ms. Eve Damiano
Ms. Eve Damiano
Senior Vice President - Regulatory
Senior Vice President - Regulatory
--
--
Ms. Melissa Gaines
Ms. Melissa Gaines
Senior Vice President - Clinical Operations
Senior Vice President - Clinical Operations
--
--
Dr. Mike Christie, Ph.D.
Dr. Mike Christie, Ph.D.
Vice President - Process Chemistry
Vice President - Process Chemistry
--
--
Mr. Mark P. Guerin, CPA
Mr. Mark P. Guerin, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Independent Chairman of the Board
Independent Chairman of the Board
2.80M
+45000.00%
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Reid S. Mccarthy
Mr. Reid S. Mccarthy
Independent Director
Independent Director
--
--
Dr. Claudine E. Bruck, Ph.D.
Dr. Claudine E. Bruck, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mark White
Mr. Mark White
Director, Chief Business Officer
Director, Chief Business Officer
--
--
Dr. Cheng Fang, Ph.D.
Dr. Cheng Fang, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: dom, 1 de fev
Atualizado em: dom, 1 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Hoffman (Michael B)
10.56%
Maccecchini (Maria-Luisa)
4.57%
Heights Capital Management, Inc.
3.77%
The Vanguard Group, Inc.
3.48%
Susquehanna International Group, LLP
0.82%
Outro
76.79%
Investidores
Investidores
Proporção
Hoffman (Michael B)
10.56%
Maccecchini (Maria-Luisa)
4.57%
Heights Capital Management, Inc.
3.77%
The Vanguard Group, Inc.
3.48%
Susquehanna International Group, LLP
0.82%
Outro
76.79%
Tipos de investidores
Investidores
Proporção
Individual Investor
15.45%
Investment Advisor
10.09%
Investment Advisor/Hedge Fund
1.63%
Research Firm
0.88%
Hedge Fund
0.70%
Venture Capital
0.11%
Family Office
0.06%
Bank and Trust
0.04%
Outro
71.05%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
95
3.04M
12.65%
--
2025Q3
100
3.04M
19.77%
+213.09K
2025Q2
100
2.82M
20.67%
-295.79K
2025Q1
97
3.12M
17.76%
-341.88K
2024Q4
86
1.59M
13.97%
+377.86K
2024Q3
78
1.21M
12.84%
+189.05K
2024Q2
74
1.03M
17.16%
-257.35K
2024Q1
70
1.29M
17.10%
-594.16K
2023Q4
71
1.27M
17.43%
-328.68K
2023Q3
74
1.16M
17.17%
-74.90K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Hoffman (Michael B)
2.84M
10.71%
+45.00K
+1.61%
Dec 08, 2025
Maccecchini (Maria-Luisa)
1.21M
4.57%
+97.56K
+8.75%
Oct 28, 2025
Heights Capital Management, Inc.
1.00M
3.77%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
738.00K
2.78%
+41.24K
+5.92%
Sep 30, 2025
Susquehanna International Group, LLP
218.42K
0.82%
+53.86K
+32.73%
Sep 30, 2025
Geode Capital Management, L.L.C.
184.15K
0.69%
+867.00
+0.47%
Sep 30, 2025
Citadel Advisors LLC
174.34K
0.66%
+145.02K
+494.51%
Sep 30, 2025
Northern Trust Investments, Inc.
112.75K
0.43%
+64.12K
+131.84%
Sep 30, 2025
Consilium Associates
81.32K
0.31%
-10.00K
-10.95%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
